Copyright
©The Author(s) 2017.
World J Hepatol. Jul 8, 2017; 9(19): 850-856
Published online Jul 8, 2017. doi: 10.4254/wjh.v9.i19.850
Published online Jul 8, 2017. doi: 10.4254/wjh.v9.i19.850
Table 1 Patient characteristics and outcomes
| Characteristic | All patients | Patients with first Hepascore > 0.75 | All patients | Patients with first Hepascore > 0.75 | ||||
| Number | Percent | Number | Percent | mean | Range | mean | Range | |
| Number | 346 | - | 100 | - | - | - | - | - |
| Gender (male) | 220 | 63.6 | 76 | 76 | - | - | - | - |
| SVR | 38 | 11.0 | 16 | 16 | - | - | - | - |
| Composite endpoint | 28 | 8.1 | 21 | 21 | - | - | - | - |
| LRD | 8 | 2.3 | 8 | 8 | - | - | - | - |
| LD | 16 | 4.6 | 12 | 12 | - | - | - | - |
| HCC | 15 | 4.3 | 12 | 12 | - | - | - | - |
| Result | - | - | - | - | ||||
| Bilirubin (μmol/L)1 | - | - | - | - | 9.0 | 1.0-200 | 12 | 2.3-200 |
| GGT (U/L)1 | - | - | - | - | 55.0 | 8.0-1005 | 93.5 | 17-713 |
| HA (μg/L)1 | - | - | - | - | 30.3 | 1.0-1211 | 124.5 | 16-1211 |
| A2M (μg/mL)1 | - | - | - | - | 2.5 | 0.6-6 | 3.6 | 1.5-6.0 |
| Age (yr) | - | - | - | - | 53.6 | 30-80 | 58.3 | 36-80 |
| Baseline Hepascore | - | - | - | - | 0.48 | 0.02-1.0 | 0.93 | 0.77-1.0 |
| Second Hepascore | - | - | - | - | 0.57 | 0.04-1.0 | 0.87 | 0.13-1.0 |
| Delta Hepascore | - | - | - | - | 0.09 | -0.80-0.94 | -0.06 | -0.8-0.23 |
| Time between baseline and second Hepascore (yr) | - | - | - | - | 3.3 | 0.03-12.5 | 2.8 | 0.03-10.3 |
| Follow-up after second Hepascore (yr) | - | - | - | - | 2.2 | 0.01-7.3 | 1.9 | 0.01-5.7 |
- Citation: Jeffrey AW, Huang Y, de Boer WB, Adams LA, MacQuillan G, Speers D, Joseph J, Jeffrey GP. Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome. World J Hepatol 2017; 9(19): 850-856
- URL: https://www.wjgnet.com/1948-5182/full/v9/i19/850.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i19.850